We cover Strava's "Quitters Day" phenomenon (January 19th), why dry January might backfire, and why positive reinforcement beats self-punishment every time
Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J
Not only can it help relieve pain associated with nerve conditions, but it can also fix and repair your nerves instead of just covering up the symptoms
What is NL-BPC-157 most effective for